日本最新免费二区三区,亚洲国产精品无码AAA片,婷婷伊人久久大香线蕉av

RD3-0028

NMR下載 COA and HPLC MSDS下載
names：
RD3-0028
CAS號：
3886-39-3
MDL Number： MFCD00945344
MF(分子式)： C8H8S2 MW(分子量)： 168.28
EINECS:No data available Reaxys Number:No data available
Pubchem ID:5278214 Brand:BIOFOUNT

RD3-0028(3886-39-3)，苯并二氫噻嗪類化合物，RD3-0028在細胞培養(yǎng)中對呼吸道合胞病毒（RSV）具有有效的抗病毒活性。當通過小顆粒氣霧劑遞送時，RD3-0028還抑制RSV的生長并改善免疫抑制小鼠的間質性肺炎的病理變化。

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
YZM000877-5mg	5mg	>95%	￥ 6085.00	￥ 6085.00		Backorder	- +	￥ 0.00
YZM000877-1mg	1mg	>95%	￥ 3656.00	￥ 3656.00		Backorder	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	RD3-0028(3886-39-3);1,4-Dihydro-2,3-benzodithiine;1,4-dihydro-2,3-benzodithiin
英文別名	RD3-0028(3886-39-3);1,4-Dihydro-2,3-benzodithiine;1,4-dihydro-2,3-benzodithiin
CAS號	3886-39-3
Inchi	InChI=1S/C8H8S2/c1-2-4-8-6-10-9-5-7(8)3-1/h1-4H,5-6H2
InchiKey	KGFBVQXWAXWGDL-UHFFFAOYSA-N
分子式 Formula	C8H8S2
分子量 Molecular Weight	168.28
溶解度Solubility
性狀	Solid
儲藏條件 Storage conditions	請根據(jù)產品建議的存儲條件進行存儲,Please store the product under the recommended condition sin the description.

RD3-0028(3886-39-3)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染
RD3-0028(3886-39-3) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:RD3-0028(3886-39-3),RD3-0028試劑,RD3-0028的純度,RD3-0028抑制劑,RD3-0028的類別,RD3-0028的毒性,RD3-0028的合成,RD3-0028的外觀,RD3-0028的作用,RD3-0028的生產,RD3-0028的用途,RD3-0028的溶解度

產品說明	RD3-0028(3886-39-3)是有效和選擇性的RSV復制的抑制劑，EC50值是4.5 μM
Introduction	RD3-0028(3886-39-3) is a potent and selective inhibitor of RSVreplication with anEC50of 4.5 μM.
Application1
Application2
Application3

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Watanabe W, et al. Novel anti-respiratory syncytial(RS) viral compounds: benzodithiin derivatives. Biochem Biophys Res Commun. 1998 Aug 28;249(3):922-6.

Sudo K, et al. Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice. Antimicrob Agents Chemother. 1999 Apr;43(4):752-7.

Sudo K, et al. Pharmacokinetics of a benzodithiin (RD3-0028) following aerosol treatment in rat.

Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028) PMID 11529559; Microbiology and immunology 2001; 45(7):531-7

Pharmacokinetics of a benzodithiin (RD3-0028) following aerosol treatment in rat PMID 11820507; Xenobiotica; the fate of foreign compounds in biological systems 2002 Jan; 32(1):19-27

Pharmacokinetics of a benzodithiin (RD3-0028) following aerosol treatment in rat
Abstract:1. RD3-0028, a benzodithiin compound, has potent antiviral activity against respiratory syncytial virus (RSV) in cell culture. The compound also inhibits growth of RSV and improves pathologic changes of interstitial pneumonia in the immunosuppressed mouse when delivered by small-particle aerosol.
2. In the present study, the absorption, distribution and excretion of 14C-RD3-0028 were compared in rat following either a single aerosol treatment or oral administration.
3. The plasma concentration was maintained at the same level from 5 min to 1 h, and decreased with a half-life of 2.2 +/- 0.1 h for 1-8 h.
4. The excretion of radioactivity in the urine and faeces at 24 h after aerosol treatment was 89.3 and 4.5%, respectively, indicating that almost all the radioactivity was rapidly excreted in the urine. The excretion of total radioactivity was 98.9% within 168 h.
5. The concentrations of radioactivity in the lung and trachea following aerosol treatment were higher than those in other tissues, and were detected even at 72 h.
6. These results suggest that the aerosol treatment might be useful for delivering RD3-0028 to the respiratory tract of RSV-infected patients.

Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028)
Abstract:RD3-0028, a compound with a benzodithiin structure, was found to be a potent inhibitor of respiratory syncytial virus (RSV) replication. Its action is specific; no activity is seen against influenza A virus, measles virus, herpes simplex virus type 1 or 2, or human cytomegalovirus. A time-dependent drug addition experiment indicated that the antiviral activity occurs in the late stage of the RSV replication cycle, since this compound completely inhibited syncytium formation even when added up to 16 hr after the infection of cell monolayers at an MOI of 3. RD3-0028 had no direct virucidal effect on RSV. Western blotting analysis showed that RD3-0028 significantly decreased the amount of RSV proteins released into the cell culture medium. Moreover, five independent isolates of the RSV long strain were selected for growth in RD3-0028 (5-20 microg/ml). These resistant viruses were more than 80-fold less sensitive to RD3-0028 than the long strain. The F gene segment of each of these viruses was sequenced and in each case the mutant RNA segment contained at least one sequence alteration, converting asparagine 276 to tyrosine (F1 protein). These results suggest that RD3-0028 inhibits RSV replication by interfering with intracellular processing of the RSV fusion protein, or a step immediately thereafter, leading to loss of infectivity.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開